Page 50

The Role of Salvestrols in the Management of Cancer Patients at the Schachter Center in New York

!"#"$!%

Michael Schachter, MD 475KZ7;TG'5eO%^:89)78*%E'/)%-0*'5% X5A7,A+8+5/KL%

475KZ7;TG'5eO%^:89)78*%E'/)%-0*'5% X5A7,A+8+5/K!% •! >0$J#-9##0$5"#3&$-.#*-3#0-,L$A/A$2#-$4$A./E,$*0A$ @?Od$3*0G$,DEE'#3#0-,$5&070D#A$ •! Sq+0%J%07?5;O%76%()+87/)+0*9:2%3*,,$,".D0;$JG$ ihk$*0A$5&20/7&0$J#5*3#$0&.3*'d$&05&'&2/,-$ -"./''#A$9/-"$.#,D'-,$ •! P(/%<C$<`%-+T*5%1755'+%F*5(+%907/7(7,%f+>/+5O'A+% )+0W*,%907T0*8g%*,75T%E'/)%7?0%907T0*8% •! F05&'&2/,-$.#5&33#0A,$3&.#$5"#3&-"#.*EG$ O/*0@5T%'5%1+(%<C$<%70%s*5%<C$LB%9*.0#A$&($*$.*E/A$ .#5D..#05#$/($-"/,$/,$0&-$A&0#$

•! PA+0*,,%/)+%9*@+5/%;';%E+,,%?9%/)07?T)%/)+%8';;,+%76% <C$<%fJ%:+*0Og%E'/)%O78+%/E+*G'5T%76%)+0%/):07';2% (75@5?+;%3%;0'9O%E'/)%-$#2%;'+/*0:%()*5T+O% •! s?,:%<C$<K1+A+,79+;%(7T5'@A+%*W5708*,'@+O2%O,?00+;% O9++()%*5;%,7OO%76%W*,*5(+B%*5%&]X%O)7E+;%*%3*,,$/0$ "#.$J.*/0$5&0,/,-#0-$9/-"$*$'G3E"&3*$ •! 375O?,/O%E'/)%4+?07K75(7,7T'O/%*/%8*a70%4F3%(*5(+0% (+5/+0% •! S?T?O/`%<C$<%3)+87/)+0*9:%0+T'8+%O/*0/+;2%W?/%O)+% 5&070D#A$-.#*-3#0-$*-$&D.$4#0-#.$*O%E+,,% ^P=%3%

^P=%3%

475KZ7;TG'5eO%^:89)78*%E'/)%-0*'5% X5A7,A+8+5/KJ%

475KZ7;TG'5eO%^:89)78*%E'/)%-0*'5% X5A7,A+8+5/KM% •! 6*7#0-$,##3,$,*7,Z#A$E'/)%/)'O%9,*5B%W?/2%&05&'&2/,-$ *0A$"D,J*0A$D0"*EEGB%W7/)%E*5/+;%)+0%/7%;7% ()+87/)+0*9:% •! ST*'5O/%/)+%E'O)+O%76%)+0%75(7,7T'O/%*5;%)?OW*5;2% 9*@+5/%W+T'5O%/)+%O*,A+O/07,%907T0*8% •! @?O$9*,$,-&EE#A$*0A$)*'+#,-.&',$9#.#$,-*.-#A$*-$$hRRR$ E&/0-,$A*/'G$S$'*-#.$/05.#*,#A$*,$"/2"$*,$?lLRRR$E&/0-,$ A*/'G$ •! 1755'+%F*5(+%907/7(7,%;0*O@(*,,:%0+;?(+;%*q+0%+5+0T:% /+O@5T%E'/)%.*,A+O/07,O%'5;'(*/+;%/)*/%O78+%76%/)+%)+0WO% 8'T)/%'5/+06+0+%E'/)%/)+%O*,A+O/07,O%

•! M.B$)5"*5"-#.$5&0,D'-#A$9/-"$E*7#0-$S$"D,J*0A$/0$ e*0D*.G$QR?W$ •! 1'O(?OO+;%.*,A+O/07,O%'5%;+9/)%*5;%O?99,'+;%E0'd+5% 8*/+0'*,%'5(,?;'5T%.()*+6+0eO%W77G%*5;%*0@(,+O% •! 10N%.%O?TT+O/O%*%/0'*,%76%)'T)%;7O+%.*,A+O/07,O2%*,75T% E'/)%XR%3%;0'9O%*5;%(75@5?+;%5?/0'@75*,%O?9970/% •! &75'/70%(*0+6?,,:%670%+A';+5(+%76%W0*'5%0+(?00+5(+% •! 3*5%*,E*:O%0+O/*0/%()+87/)+0*9:%'6%(7T5'@A+% 907W,+8O%0+*99+*0%*5;"70%*W5708*,'@+O%75%&]X%

^P=%3%

^P=%3%

%

475KZ7;TG'5eO%^:89)78*%E'/)%-0*'5% X5A7,A+8+5/K#%

475KZ7;TG'5eO%^:89)78*%E'/)%-0*'5% X5A7,A+8+5/KI% •! -:%I%70%H%875/)O%*q+0%()+87/)+0*9:%)*O%W++5% 0+(788+5;+;2%O@,,%57%0+/?05%76%5+?07%O>O% •! S%W.A$1%>$9*,$A&0#$fE'/)7?/%T*;7,'5'?8g%*5;%E*O% *T*'5%5+T*@A+% •! F05&'&2/,-$*3*U#A$,"#$"*,$"*A$0&$.#5D..#05#$*5;%'O% 57%,75T+0%9?O)'5T%()+87/)+0*9:B%O)+%(75@5?+O%/7%T+/% *%W0*'5%&]X%+A+0:%L%875/)O% •! 47E2%$J%875/)O%6078%@8+%()+87%0+(788+5;+;%6++,O% T0+*/%f5?/0'@75*,%907T0*8%/E+*G+;%E'/)% 0+(788+5;*@75O%76%)'T)%;7O+O%76%A'/*8'5%1%*5;%t<% f&t!gB%SO:89/78*@(B%O++8O%h5+%

•! S/%L%875/)O%*q+0%()+87%0+(788+5;+;2% 75(7,7T'O/%O@,,%9?O)'5T%()+87/)+0*9:2%W?/% 9*@+5/%0+O'O/*5/% •! ?,-$1%>$*/%*W7?/%W$3&0-",$*q+0%()+87/)+0*9:% E*O%0+(788+5;+;%'O%0#2*7+#%f75(7,7T'O/% O?090'O+;g% •! T-$l$3&0-",2%9*@+5/%O@,,%)*O%0&$0#D.&'&2/5*'$ ,G3E-&3,$S$Q0A$1%>$0#2*7+#2%/)7?T)%O)+% 0+*(/+;%/7%T*;7,'5'?8$f+>/+5O'A+%)'A+Og%

^P=%3%

^P=%3%

49

#%